Digoxin-specific antibody fragments are engineered proteins that bind selectively to digoxin, a cardiac glycoside used to treat heart failure and atrial fibrillation. These fragments are crucial in clinical practice for reversing life-threatening digoxin toxicity, particularly in patients presenting with arrhythmias or severe symptoms. An important association is their use in cases of overdose, where timely administration can significantly reduce morbidity and mortality.